Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

Restaurant Brands International reported quarterly adjusted earnings per share of 81 cents and revenue of $2.3 billion.

Europe's biggest gas distributor Italgas reported on Wednesday a 14% annual rise in its 2024 adjusted core earnings, as it ...

Norway's Ocean Industry Authority said on Wednesday it has given Gassco and Shell consent for the startup of production from ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...